A new test quickly shows if an antibiotic fights a given infection, which can reduce improperly prescribed antibiotics.

J&J is now assessing what it will take to quell the FDA’s concerns about the safety of the IL-6 monoclonal antibody before deciding on a path forward.

AbbVie joins forces with Bristol-Myers Squibb once again to test an experimental cancer drug with BMS' checkpoint inhibitor Opdivo.

Versartis’ somavaratan has failed to match Pfizer’s Genotropin in phase 3, wiping more than 80% off its stock price.

Andrew Witty jumped into biotech venture capital, Aerie poached another exec from Alcon, Roivant tapped Silicon Valley vet to run trial AI company.

In this week's EuroBiotech Report, phase 3 data send Bavarian Nordic and Nabriva in opposite directions, Immunocore raises $40 million and more. 

In our EuroBiotech roundup this week, Autolus advances CAR-T trial, Cell Medica names CSO and AB Science suffers a regulatory setback.

The decision positions the Celgene-backed cancer immunotherapy biotech to move oral small molecule FLX475 into the clinic later this year.

After a $28 million financing, Provention Bio has grabbed two IBD candidates from Janssen that should make it a double clinical-stage biotech in 2018.